Sage Therapeutics (NASDAQ:SAGE) is reportedly suing Biogen (NASDAQ:BIIB) over enforcement of a standstill agreement in the ...

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

Sage stock rose 35% to $7.51 in premarket trading Monday; it closed at $5.55 on Friday. Biogen shares dipped 0.5% to $48.01.

A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) have been assigned a consensus rating of “Hold” from the ...

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

As I ran from interview to interview across San Francisco, I was consistently warmed by the stories I was told by biotech and ...

The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by ...

Truist keeps a Hold rating on Sage Therapeutics (SAGE) after Zurzurvae’s commercial partner Biogen (BIIB) disclosed an unsolicited proposal to acquire the company for $7.22 per share.

Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...